| 证券代码：300891 | 证券简称：惠云钛业 | 公告编号：2026-007 | | --- | --- | --- | | 债券代码：123168 | 债券简称：惠云转债 | | 广东惠云钛业股份有限公司 关于持股 5%以上股东减持股份预披露公告 持股 5%以上的股东朝阳投资有限公司保证向本公司提供的信息内容真实、 准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 持有广东惠云钛业股份有限公司（以下简称"公司"） 52,696,600 股（占本公 司总股本比例 13.1739%）的股东朝阳投资有限公司（以下简称"朝阳投资"）， 计划在本公告披露之日起 15 个交易日后的 3 个月内（即 2026 年 4 月 18 日至 2026 年 7 月 17 日，下同）以集中竞价和大宗交易方式合计减持公司股份不超过 11,920,900 股（占公司总股本的 2.9802%，占公司总股本剔除回购专用账户中股 份后的 3.0000%），其中：以集中竞价方式合计减持不超过 3,973,662 股（占公 司总股本的 0.9934%，占公司总股 ...

| 证券代码：300891 | 公司简称：惠云钛业 | 公告编号：2026-006 | | --- | --- | --- | | 债券代码：123168 | 债券简称：惠云转债 | | 广东惠云钛业股份有限公司 关于公司被评为2025年度国家级 "绿色工厂"的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或者重大遗漏。 一、基本情况 广东惠云钛业股份有限公司董事会 2026年3月18日 1 本次获评2025年度国家级"绿色工厂"，是对公司长期专注于绿色生产和开 展节能低碳减排升级改造工作的肯定与鼓励，为今后深化绿色发展明确了方向。 未来，公司将进一步推动可持续发展理念，深化绿色工厂建设，聚焦节能低碳减 排生产技术的研发与应用，提高能源资源利用效率，减少污染物的产生和排放， 实现经济效益、生态效益与社会效益的协调发展，促进企业高质量发展。 上述信息不会对公司的经营业绩产生重大影响。敬请广大投资者注意投资风 险。 三、备查文件 《工业和信息化厅2025年度绿色工厂名单》。 根据《绿色工厂梯度培育及管理暂行办法》和《工业和信息化部办公厅关于 开展2025年度绿色工厂推荐 ...

Group 1 - Anada and Jinfeng Titanium Industry have previously reached their trading limits, indicating strong market interest [1] - Companies such as Vanadium Titanium Co., Zhenhua Co., Titanium Chemical, Longbai Group, and Huiyun Titanium Industry have all seen stock increases of over 5% [1]

Core Viewpoint - The company Huayun Titanium Industry (300891) has disclosed its 2025 annual performance forecast, indicating a projected net loss attributable to shareholders of between -65 million and -46 million yuan, primarily due to intensified industry competition, declining product prices, and increased project conversion costs [1][2] Financial Performance - The company expects a net profit for 2025 to be in the range of -65 million to -46 million yuan, with the loss driven by factors such as heightened industry competition, falling product prices, and rising project conversion expenses [2]

Core Viewpoint - Huiyun Titanium Industry (300891) expects steady revenue growth for the year 2025, with a projected net loss attributable to shareholders ranging from 65 million to 46 million yuan [1]. Group 1 - The company anticipates operating revenue to grow steadily from January 1, 2025, to December 31, 2025 [1]. - The projected net profit loss for the company is estimated to be between 65 million yuan and 46 million yuan [1].

Financial Performance - The company expects a net profit of approximately -65 million yuan for 2025, compared to -46 million yuan in the same period last year, representing a 42.08% increase in losses [5]. - The net profit after deducting non-recurring gains and losses is projected to be around -69 million yuan, compared to -50 million yuan in the previous year, indicating a 41.03% increase in losses [5]. - The performance forecast is based on preliminary estimates by the company's finance department and has not yet been audited by the accounting firm [6]. - Investors are advised to pay attention to investment risks as the actual financial data will be disclosed in the official 2025 annual report [9]. Revenue and Sales Outlook - The company anticipates steady growth in titanium dioxide sales and overall revenue, despite the expected net loss due to increased depreciation and interest expenses from previous fundraising and technical transformation projects [7]. Operational Strategies - The company plans to enhance production efficiency and leverage circular economy advantages, focusing on extending the industrial chain around its main business [8]. - Future strategies include technology research and development, process and product optimization, and differentiation through boutique strategies and personalized production [8]. - The company acknowledges that while production capacity is gradually being released, achieving full production and synergistic efficiency will require additional time [7].

Core Viewpoint - The medical titanium alloy industry is experiencing significant growth driven by an aging population and increasing chronic disease rates, leading to higher demand for medical devices and implants. The market size for medical titanium alloys in China is projected to reach 4.32 billion yuan in 2024, reflecting a 9% year-on-year increase [1][6]. Group 1: Industry Overview - Medical titanium alloys are specialized biocompatible materials used for manufacturing human implants, characterized by excellent biocompatibility, high specific strength (over 300 MPa·cm³/g), and moderate elastic modulus (approximately 110 GPa) [3]. - The development of medical titanium alloys has progressed through three generations, with the latest generation focusing on reducing toxicity and improving compatibility with human bone [3][4]. Group 2: Market Size and Growth - The market for medical titanium alloys is expected to continue growing, with the orthopedic implant sector (including artificial joints and spinal correction devices) holding the largest market share at 50%, projected to reach 2.16 billion yuan in 2024 [6]. - Factors driving demand in the orthopedic implant sector include an aging population (over 300 million people aged 60 and above in China), advancements in medical technology, and supportive policies [6]. Group 3: Competitive Landscape - The medical titanium alloy industry features a concentrated head with leading companies like Baotai Co., West Superconductor, and Xiangtou Jintian dominating the mid-to-high-end market, while smaller firms focus on niche segments to avoid direct competition [7]. - Key players in the industry include Jiangsu Tiangong Technology Co., Baotai Co., and others, with a focus on R&D and production of titanium and titanium alloy materials [7][8]. Group 4: Industry Trends - The industry is moving towards functional upgrades of materials to meet diverse clinical needs, emphasizing the development of new alloys that are aluminum and vanadium-free for enhanced biocompatibility [9]. - Integration of smart technologies into titanium alloy products is becoming a significant innovation direction, with the incorporation of micro-sensors for real-time monitoring of implant conditions [10]. - The industry is accelerating its green and low-carbon transformation, focusing on energy-efficient production processes and recycling systems for titanium alloy materials to reduce waste and production costs [11].

广东惠云钛业股份有限公司 章 程 （核准版本） | | | 第 一 章 总 则 第一条 为维护公司、股东、职工和债权人的合法权益，规范公司的组织 和行为，根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华 人民共和国证券法》（以下简称"《证券法》"）、《上市公司治理准则》和其 他有关规定，制定本章程。 第二条 广东惠云钛业股份有限公司（以下简称"公司"）系依照《公司法》 和其他有关规定成立的股份有限公司。 公司由云浮市惠沄钛白有限公司以整体变更方式发起设立，在广东省云浮 市市场监督管理局登记注册，取得企业法人营业执照，统一社会信用代码为 914453007545211876。 第三条 公司于 2020 年 8 月 17 日经中国证券监督管理委员会（以下简称 "中国证监会"）同意注册，首次向社会公众发行人民币普通股 10,000 万股，并 于 2020 年 9 月 17 日在深圳证券交易所上市。 第四条 公司注册名称：广东惠云钛业股份有限公司 公司英文全称：Guangdong Huiyun Titanium Industry CO. LTD. 第五条 公司住所：云浮市云安区六都镇，邮编：527500 ...

广东惠云钛业股份有限公司 关于完成经营范围变更登记和章程修订备案并换发营业执照的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、基本情况 广东惠云钛业股份有限公司（以下简称"公司"）于 2025 年 12 月 22 日召开 的第五届董事会第十六次会议、2026 年 1 月 13 日召开的 2026 年第一次临时股 东会，审议通过《关于增加经营范围和修订<公司章程>并提请股东会授权董事会 全权办理公司备案事项的议案》，同意增加公司经营范围以及对《公司章程》的 相应条款进行修订，授权董事会到市场监督管理部门办理增加经营范围、章程修 订等相关事宜备案，并授权董事会及其授权办理人员按照市场监督管理部门或其 他政府有关部门提出的审批意见或要求对相关文件进行必要的修改，具体变更情 况以当地的市场监督管理部门登记备案为准。具体内容详见公司在巨潮资讯网 （http://www.cninfo.com.cn）披露的《关于增加经营范围和修订<公司章程>并提 请股东会授权董事会全权办理公司备案事项的公告》（公告编号：2025-100）。 二、进展情况 | 证券代码：3008 ...

Group 1 - The company Huayun Titanium Industry's wholly-owned subsidiary, Qinghe Huayun Mining Co., Ltd., is engaged in non-ferrous metal mining and has obtained exploration rights for the "Xinjiang Qinghe Akvana Vanadium-Titanium Magnetite Mine," currently in the preliminary exploration stage [2] - The company's controlling subsidiary, Guangnan Chenxiang Mineral Development Co., Ltd., focuses on the mining, processing, and sales of titanium ore and holds mining rights for the "Guangnan Sandou Namo Titanium Mine," which contains titanium iron ore and associated magnetite, and is currently in the process of obtaining relevant mining permits [2]